ASBP Relative Valuation
ASBP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ASBP is overvalued; if below, it's undervalued.
Historical Valuation
Aspire Biopharma Holdings Inc (ASBP) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of Aspire Biopharma Holdings Inc (ASBP) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：0.10
Fair
0.00
PE
1Y
3Y
5Y
0.00
EV/EBITDA
Aspire Biopharma Holdings Inc. (ASBP) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
0.00
EV/EBIT
Aspire Biopharma Holdings Inc. (ASBP) has a current EV/EBIT of 0.00. The 5-year average EV/EBIT is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBIT of 0.00 falls within the Strongly Undervalued range.
0.00
PS
Aspire Biopharma Holdings Inc. (ASBP) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.
0.00
P/OCF
Aspire Biopharma Holdings Inc. (ASBP) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.
0.00
P/FCF
Aspire Biopharma Holdings Inc. (ASBP) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.
Aspire Biopharma Holdings Inc (ASBP) has a current Price-to-Book (P/B) ratio of -0.59. Compared to its 3-year average P/B ratio of -300.69 , the current P/B ratio is approximately -99.80% higher. Relative to its 5-year average P/B ratio of -300.69, the current P/B ratio is about -99.80% higher. Aspire Biopharma Holdings Inc (ASBP) has a Forward Free Cash Flow (FCF) yield of approximately -23.90%. Compared to its 3-year average FCF yield of -15.71%, the current FCF yield is approximately 52.11% lower. Relative to its 5-year average FCF yield of -15.71% , the current FCF yield is about 52.11% lower.
-0.59
P/B
Median3y
-300.69
Median5y
-300.69
-23.90
FCF Yield
Median3y
-15.71
Median5y
-15.71
Competitors Valuation Multiple
The average P/S ratio for ASBP's competitors is 0.14, providing a benchmark for relative valuation. Aspire Biopharma Holdings Inc Corp (ASBP) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ASBP increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ASBP in the past 1 year is driven by Unknown.
People Also Watch
WMT
Walmart Inc
113.07USD
0.31%
MSFT
Microsoft Corp
478.11USD
-1.11%
META
Meta Platforms Inc
646.06USD
-0.41%
AVGO
Broadcom Inc
332.48USD
-3.21%
AAPL
Apple Inc
259.04USD
-0.50%
AMZN
Amazon.com Inc
246.26USD
1.95%
TSLA
Tesla Inc
435.8USD
1.02%
ORCL
Oracle Corp
189.65USD
-1.65%
NVDA
NVIDIA Corp
185.04USD
-2.15%
XOM
Exxon Mobil Corp
122.91USD
3.73%
Frequently Asked Questions
Is Aspire Biopharma Holdings Inc (ASBP) currently overvalued or undervalued?
Aspire Biopharma Holdings Inc (ASBP) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of Aspire Biopharma Holdings Inc (ASBP) is between to according to relative valuation methord.
What is Aspire Biopharma Holdings Inc (ASBP) fair value?
ASBP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Aspire Biopharma Holdings Inc (ASBP) is between to according to relative valuation methord.
How does ASBP's valuation metrics compare to the industry average?
The average P/S ratio for ASBP's competitors is 0.14, providing a benchmark for relative valuation. Aspire Biopharma Holdings Inc Corp (ASBP) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Aspire Biopharma Holdings Inc (ASBP) as of Jan 08 2026?
As of Jan 08 2026, Aspire Biopharma Holdings Inc (ASBP) has a P/B ratio of -0.59. This indicates that the market values ASBP at -0.59 times its book value.
What is the current FCF Yield for Aspire Biopharma Holdings Inc (ASBP) as of Jan 08 2026?
As of Jan 08 2026, Aspire Biopharma Holdings Inc (ASBP) has a FCF Yield of -23.90%. This means that for every dollar of Aspire Biopharma Holdings Inc’s market capitalization, the company generates -23.90 cents in free cash flow.
What is the current Forward P/E ratio for Aspire Biopharma Holdings Inc (ASBP) as of Jan 08 2026?
As of Jan 08 2026, Aspire Biopharma Holdings Inc (ASBP) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of Aspire Biopharma Holdings Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Aspire Biopharma Holdings Inc (ASBP) as of Jan 08 2026?
As of Jan 08 2026, Aspire Biopharma Holdings Inc (ASBP) has a Forward P/S ratio of 0.00. This means the market is valuing ASBP at $0.00 for every dollar of expected revenue over the next 12 months.